An interventional study of Weight reduction program and Lecture on healthy nutrition in Stroke and Obesity, sponsored by Philipps University Marburg. Status unknown at 1 site in Germany. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2012-11-04.
Sponsored by Philipps University Marburg · Not applicable, Interventional, and Prevention
SCENARIO is a trial to investigate the role of non-drug weight reduction in secondary prevention of stroke. It is a single-blinded, randomized, controlled multicentre trial with two arms. The therapy arm is participating in a comprehensive weight reducing program, whereas the control group takes part in a lecture on healthy nutrition. The primary study objective is to assess the efficacy of non-drug therapeutic weight reduction in the secondary prevention of stroke. Secondary objectives are functional outcome, cognitive status, post stroke depression, and health-related quality of life.
7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.
This study's planned enrollment of 200 is above the median of 50 across 5,369 interventional studies indexed under Stroke.
Browse Stroke studies →Philipps University Marburg is the lead sponsor of 114 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Severe co-morbid disorders, e.g.:
Non-drug therapeutic weight reduction program (15 weeks)
Other: Weight reduction program
Lecture on healthy nutrition (1 hour)
Other: Lecture on healthy nutrition
The primary endpoint is the number of deaths or major vascular events defined as stroke, TIA, myocardial infarction or hospitalization due to angina pectoris, which occur between the randomization and last follow-up.
Time frame: 18 months
Functional outcome
Functional outcome as measured by the modified Rankin Scale (mRS), NIH Stroke Scale (NIHSS) and Barthel Index (BI)
Time frame: 18 months
Cognitive deficits
Cognitive deficits in terms of vascular dementia as measured by the Structural Interview for diagnosis of Alzheimer dementia and multi-infarct dementia (SIDAM), the Vascular Dementia Assessment Scale cognitive subscale (VADAS-Cog), Stroop test and the Trail Makin Test
Time frame: 18 months
Post stroke depression
Post stroke depression as measured by Beck Depression Inventar (BDI II) and health-related quality of life (HrQoL) as measured by the EuroQol (EQ5D, visual analogue scale), Stroke Specific Quality of Life Scale, Stroke Impact Scale.
Time frame: 18 months
Severity of arterial hypertension, diabetes mellitus and hyperlipidemia
Time frame: 18 months
This study is status unknown, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Philipps University Marburg